This site is intended for health professionals only

Published on 12 April 2019

Share this story:
Twitter
LinkedIn

Janssen announces first two data centres to join HONEUR collaborative network

HONEUR (Haematology Outcomes Network in Europe) is a Janssen-led initiative and part of the company’s overall commitment to creating better outcomes for patients – in this case, by harnessing the full potential of Real World Data and the insights it can provide. 
Through a secure, collaborative platform, HONEUR enables participants across Europe to accelerate research and improve conclusions by analysing treatment data from as many sources as possible. The ultimate goal is that patients with blood cancer would receive the best possible treatment due to health data research being widely shared and smartly managed.
The first site to join the HONEUR network is the UK’s Leicester Royal Infirmary. Dr Mamta Garg, Consultant Haematologist, MD, FRCP, FRCPath (Haematology), said, “My colleagues and I at the Leicester Royal Infirmary are passionate about the development and use of database records in haematological disorders,as they provide a source of invaluable information for benchmarking, education and research purposes. Joining HONEUR brings us a big step closer to generating Real World Evidence that ultimately has a meaningful impact on patients.”
Also joining the HONEUR initiative is The Registry of Monoclonal Gammopathies (RMG) in the Czech Republic. Established in 2007, the RMG is funded by the Czech Myeloma Group (CMG) and has become one of their flagship projects. “We are delighted to be one of the first sites to become an HONEUR member,”said Prof MUDr Roman Hájek, CSc. “Our registry currently includes four haematological malignancies (multiple myeloma; monoclonal gammopathies of undetermined significance; AL amyloidosis; and Waldeströms macroglobulinemia) and we are very much looking forward to collaborating with Janssen and other HONEUR members, so that we can make significant inroads in treating patients with these rare blood diseases.”


Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn